NEW YORK (GenomeWeb) — GeneFirst, a three-year-old UK-based molecular diagnostics firm, is looking to parlay its portfolio of proprietary PCR technologies into products for highly multiplexed infectious disease diagnosis and blood-based cancer mutation detection.

Leveraging three active grants totaling £670,000 (about $1.1 million) from the UK government, Abingdon-based GeneFirst will seek CE marking within the next 18 months for an assay that can detect, quantify, and genotype all 14 high-risk human papillomavirus strains in a single, closed-tube reaction.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.